Back

Long-term non-cardiovascular morbidity risk remains elevated following myocardial infarction: a nationwide cohort study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: What defines risk in acute coronary syndromes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Daniel Molager Christensen

Herlev Hospital, Herlev (Denmark)

5 More presentations in this session

Presentation thumbnail
Bleeding risk in patients hospitalized for non-ST-segment elevation acute coronary syndromes in Switzerland: performance of the CRUSADE score
Doctor F. Wenzl (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Clinical risk scores versus simple integrated clinical judgment in patients with suspected acute coronary syndromes
Doctor J. Boeddinghaus (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Metabolic associated fatty liver disease increases risk of adverse events after acute coronary syndrome.
Doctor N. Chew (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Sex inequities in the performance of the GRACE 2.0 score in non-ST-segment elevation acute coronary syndromes: a multinational observational study in contemporary cohorts from four European countries
Doctor F. Wenzl (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Association of ischemic and bleeding events with mortality in patients with a recent acute myocardial infarction
Ms M. Simonsson (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
What defines risk in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Assessing one-year risk of heart failure following first time myocardial infarction and subsequent five-year mortality risk: a nationwide study of 34,401 patients
thumbnail
Congress Presentation
Myocardial infarction mortality after COVID-19: a nationwide population-based cohort study
thumbnail
Congress Presentation
Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources